Jagsonpal Pharmaceuticals Limited Stock Current Valuation
| JAGSNPHARM | 636.65 9.80 1.52% |
Valuation analysis of Jagsonpal Pharmaceuticals helps investors to measure Jagsonpal Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of now, Jagsonpal Pharmaceuticals' Change In Cash is decreasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Free Cash Flow is estimated to increase to about 366.6 M, while Other Cashflows From Financing Activities is projected to decrease to (15.2 M). Fundamental drivers impacting Jagsonpal Pharmaceuticals' valuation include:
Price Book 8.7064 | Enterprise Value 16.5 B | Enterprise Value Ebitda 44.0489 | Price Sales 7.45 | Trailing PE 70.8176 |
Undervalued
Today
Please note that Jagsonpal Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Jagsonpal Pharmaceuticals is based on 3 months time horizon. Increasing Jagsonpal Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jagsonpal Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jagsonpal Stock. However, Jagsonpal Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 636.65 | Real 757.61 | Hype 654.59 |
The intrinsic value of Jagsonpal Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Jagsonpal Pharmaceuticals' stock price.
Estimating the potential upside or downside of Jagsonpal Pharmaceuticals Limited helps investors to forecast how Jagsonpal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jagsonpal Pharmaceuticals more accurately as focusing exclusively on Jagsonpal Pharmaceuticals' fundamentals will not take into account other important factors: Jagsonpal Pharmaceuticals Limited Company Current Valuation Analysis
Jagsonpal Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Jagsonpal Pharmaceuticals Current Valuation | 16.46 B |
Most of Jagsonpal Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jagsonpal Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Jagsonpal Pharmaceuticals Limited has a Current Valuation of 16.46 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is notably lower than that of the firm.
Jagsonpal Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jagsonpal Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jagsonpal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jagsonpal Pharmaceuticals by comparing valuation metrics of similar companies.Jagsonpal Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Jagsonpal Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0605 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 16.46 B | ||||
| Shares Outstanding | 26.55 M | ||||
| Shares Owned By Insiders | 76.28 % | ||||
| Shares Owned By Institutions | 1.47 % | ||||
| Price To Book | 8.71 X | ||||
| Price To Sales | 7.45 X | ||||
| Revenue | 2.09 B | ||||
| Gross Profit | 1.43 B | ||||
| EBITDA | 323.46 M | ||||
| Net Income | 224.63 M | ||||
| Cash And Equivalents | 110.53 M | ||||
| Total Debt | 89.41 M | ||||
| Book Value Per Share | 74.42 X | ||||
| Cash Flow From Operations | 351.66 M | ||||
| Earnings Per Share | 8.99 X | ||||
| Number Of Employees | 1.02 K | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 16.9 B | ||||
| Total Asset | 2.17 B | ||||
| Retained Earnings | 1.04 B | ||||
| Working Capital | 1.8 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 2.17 B |
About Jagsonpal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jagsonpal Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jagsonpal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jagsonpal Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jagsonpal Stock
Jagsonpal Pharmaceuticals financial ratios help investors to determine whether Jagsonpal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jagsonpal with respect to the benefits of owning Jagsonpal Pharmaceuticals security.